Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.

de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, Verweij J, Marsh S, Sparreboom A.

Clin Pharmacol Ther. 2007 Jan;81(1):42-9.

PMID:
17185998
2.

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.

Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS.

Cancer. 2007 Jul 1;110(1):138-47. Erratum in: Cancer. 2010 Aug 1;116(15):3749.

3.

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL.

Clin Cancer Res. 2003 Aug 15;9(9):3246-53.

4.

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y.

Cancer Res. 2000 Dec 15;60(24):6921-6.

5.

Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).

Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, Ishida H, Mizuno K, Matsunaga M, Araki K, Tanaka R, Ichikawa W, Miya T, Narabayashi M, Akiyama Y, Kawara K, Ando Y, Sasaki Y.

Biol Pharm Bull. 2008 Nov;31(11):2137-42.

6.

Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.

Hu ZY, Yu Q, Zhao YS.

Eur J Cancer. 2010 Jul;46(10):1856-65. doi: 10.1016/j.ejca.2010.02.049. Epub 2010 Mar 23. Review.

PMID:
20335017
7.

UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.

Stewart CF, Panetta JC, O'Shaughnessy MA, Throm SL, Fraga CH, Owens T, Liu T, Billups C, Rodriguez-Galindo C, Gajjar A, Furman WL, McGregor LM.

J Clin Oncol. 2007 Jun 20;25(18):2594-600.

8.

Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.

Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y, Koizumi W, Kakeji Y, Ishizuka N, Hyodo I, Sakata Y.

Cancer Sci. 2011 Oct;102(10):1868-73. doi: 10.1111/j.1349-7006.2011.02030.x. Epub 2011 Aug 12.

9.

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.

Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ.

Pharmacogenomics J. 2002;2(1):43-7.

PMID:
11990381
10.

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.

Soepenberg O, Dumez H, Verweij J, de Jong FA, de Jonge MJ, Thomas J, Eskens FA, van Schaik RH, Selleslach J, Ter Steeg J, Lefebvre P, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT.

Clin Cancer Res. 2005 Feb 15;11(4):1504-11.

11.

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.

de Jong FA, Kehrer DF, Mathijssen RH, Creemers GJ, de Bruijn P, van Schaik RH, Planting AS, van der Gaast A, Eskens FA, Janssen JT, Ruit JB, Verweij J, Sparreboom A, de Jonge MJ.

Oncologist. 2006 Sep;11(8):944-54.

12.

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.

Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N.

Pharmacogenet Genomics. 2007 Jul;17(7):497-504.

PMID:
17558305
13.

UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.

Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S, Shimizu A, Fukushima M, Inui K.

Int J Clin Oncol. 2009 Apr;14(2):136-42. doi: 10.1007/s10147-008-0821-z. Epub 2009 Apr 24.

PMID:
19390945
14.

UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.

Gao J, Zhou J, Li Y, Lu M, Jia R, Shen L.

Med Oncol. 2013;30(3):604. doi: 10.1007/s12032-013-0604-x. Epub 2013 May 18.

PMID:
23686699
15.

Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.

Dias MM, McKinnon RA, Sorich MJ.

Pharmacogenomics. 2012 Jun;13(8):889-99. doi: 10.2217/pgs.12.68.

PMID:
22676194
16.

UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.

Biason P, Masier S, Toffoli G.

J Chemother. 2008 Apr;20(2):158-65. Review.

PMID:
18467239
17.

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.

Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ.

J Clin Oncol. 2009 Jun 1;27(16):2604-14. doi: 10.1200/JCO.2008.20.6300. Epub 2009 Apr 6.

18.

Irinotecan pharmacogenetics: influence of pharmacodynamic genes.

Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, Paré L, Culverhouse R, McLeod HL, Baiget M.

Clin Cancer Res. 2008 Mar 15;14(6):1788-96. doi: 10.1158/1078-0432.CCR-07-1472.

19.

Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients.

Hirasawa A, Zama T, Akahane T, Nomura H, Kataoka F, Saito K, Okubo K, Tominaga E, Makita K, Susumu N, Kosaki K, Tanigawara Y, Aoki D.

J Hum Genet. 2013 Dec;58(12):794-8. doi: 10.1038/jhg.2013.105. Epub 2013 Oct 3. Erratum in: J Hum Genet. 2013 Dec;58(12):825.

PMID:
24088669
20.

Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.

Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A.

J Natl Cancer Inst. 2004 Nov 3;96(21):1585-92.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk